Dissertations from the group
|
2024
2024
2023 |
Anna Mestre Borras
Luke Parks
Linnea Hjelm |
Engineering affibody-based prodrugs for enhanced tissue selectivity (co-sup. w. Löfblom as main supervisor)
Development of directed-evolution methods utilizing combinatorial protein libraries in Escherichia coli (co-sup. w. Löfblom as main supervisor)
Development of new affinity proteins for neurodegenerative disorders (co-sup. w. Löfblom as main supervisor) |
|
2022 |
Charles Dahlsson Leitao |
Affibody-mediated targeting of HER-family receptors for cancer imaging and therapy |
|
2020 |
Sebastian Meister |
Amyloid beta, biotherapy target and biotechnological tool |
|
2020 |
Rezan Güler |
Affibody molecules targeting VEGFR2, two turns off and four turns on (co-sup. w. Löfblom as main supervisor) |
|
2017 |
Ken Andersson |
Combinatorial protein engineering of affibody molecules using E. coli display (co-sup. w. Löfblom as main supervisor) |
|
2017 |
Tarek Bass |
Affibody molecules targeting HER3 for cancer therapy |
|
2015 |
Hanna Lindberg |
Engineering of affibody molecules targeting the Alzheimer’s-related amyloid ß peptide |
|
2015 |
Lisa Sandersjöö |
Bacterial methods for characterization of proteases and affinity proteins (co-sup. w. Löfblom as main supervisor) |
|
2014
2013 |
Filippa Fleetwood
Magdalena Malm |
Bacterial display systems for engineering of affinity proteins (co-supervised with J. Löfblom as main supervisor)
Generation of affibody molecules targeting HER3 |
|
